Natco Pharma Limited has completed the allotment of equity shares pursuant to its Rights Issue. The Fund Raising Committee, at its meeting held on October 23, 2026, approved the allotment of 1,70,58,082 Equity Shares at a price of ₹750 per Equity Share (including a premium of ₹748 per Equity Share).
The meeting commenced at 8:30 PM and concluded at 8:55 PM on October 23, 2026.
This allotment follows the Board of Directors' approval on September 9, 2026, for the offer and issue of Equity Shares on a Rights Basis to eligible Equity Shareholders. The terms of the Issue were approved by the Board on September 25, 2026, and the Letter of Offer was approved by the Fund Raising Committee on September 28, 2026.
The basis of allotment was finalized in consultation with the Designated Stock Exchange, National Stock Exchange of India Limited.
Capital Structure Impact
Pursuant to the allotment, the company's paid-up equity share capital has increased from ₹35,82,19,740 (comprising 17,91,09,870 fully paid-up equity shares of face value ₹2 each) to ₹39,23,35,904 (comprising 19,61,67,952 fully paid-up equity shares of face value ₹2 each).
Additional Information
The disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information will be available on the company's website at https://files.natcopharma.co.in/investor-relations/rights-issue-2026/.
The letter was digitally signed by Venkat Ramesh Chekuri, Company Secretary & Compliance Officer, on October 23, 2026, at 20:58:59 +05:30.